11Feb/13

Cardiorentis initiates first-ever acute heart failure Phase III clinical trial … – PharmiWeb.com (press release)

Cardiorentis initiates first-ever acute heart failure Phase III clinical trial
PharmiWeb.com (press release)
Cardiorentis has initiated the first-ever acute heart failure (AHF) Phase III trial to be specifically designed to assess the effect of early treatment on cardiovascular mortality. TRUE-AHF (TRial of Ularitide’s Efficacy and safety in patients with

and more »

11Feb/13

Life Technologies Receives FDA 510(k) Clearance for Diagnostic Use of Sanger … – PR Newswire (press release)

Life Technologies Receives FDA 510(k) Clearance for Diagnostic Use of Sanger
PR Newswire (press release)
11, 2013 /PRNewswire/ — Life Technologies Corporation (NASDAQ: LIFE) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 3500 Dx Genetic Analyzers and SeCore® HLA typing kits. The development

and more »

11Feb/13

Cardiorentis initiates first-ever acute heart failure Phase III clinical trial … – PR Newswire (press release)

Cardiorentis initiates first-ever acute heart failure Phase III clinical trial
PR Newswire (press release)
Cardiorentis has initiated the first-ever acute heart failure (AHF) Phase III trial to be specifically designed to assess the effect of early treatment on cardiovascular mortality. TRUE-AHF (TRial of Ularitide’s Efficacy and safety in patients with

and more »